HK1199251A1 - 1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands 14-[322] - Google Patents
1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands 14-[322]Info
- Publication number
- HK1199251A1 HK1199251A1 HK14112780.3A HK14112780A HK1199251A1 HK 1199251 A1 HK1199251 A1 HK 1199251A1 HK 14112780 A HK14112780 A HK 14112780A HK 1199251 A1 HK1199251 A1 HK 1199251A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nonanes
- diazabicyclo
- acetylcholine receptor
- receptor ligands
- nicotinic acetylcholine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526181P | 2011-08-22 | 2011-08-22 | |
| PCT/US2012/051518 WO2013028587A1 (en) | 2011-08-22 | 2012-08-20 | 1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1199251A1 true HK1199251A1 (en) | 2015-06-26 |
Family
ID=46785810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112780.3A HK1199251A1 (en) | 2011-08-22 | 2014-12-22 | 1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands 14-[322] |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20140249141A1 (xx) |
| EP (1) | EP2748170A1 (xx) |
| JP (1) | JP2014524470A (xx) |
| KR (1) | KR20140068079A (xx) |
| CN (1) | CN103797016A (xx) |
| AR (1) | AR087602A1 (xx) |
| AU (1) | AU2012299077A1 (xx) |
| BR (1) | BR112014004068A2 (xx) |
| CA (1) | CA2844764A1 (xx) |
| CL (1) | CL2014000417A1 (xx) |
| CO (1) | CO6920290A2 (xx) |
| HK (1) | HK1199251A1 (xx) |
| IL (1) | IL230889A0 (xx) |
| MX (1) | MX2014002005A (xx) |
| PE (1) | PE20141247A1 (xx) |
| RU (1) | RU2014110971A (xx) |
| SG (1) | SG2014011126A (xx) |
| TW (1) | TW201311698A (xx) |
| UY (1) | UY34281A (xx) |
| WO (1) | WO2013028587A1 (xx) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115181778A (zh) * | 2015-02-04 | 2022-10-14 | 百时美施贵宝公司 | 选择治疗性分子的方法 |
| CN117402117B (zh) * | 2023-12-15 | 2024-03-19 | 南京威凯尔生物医药科技有限公司 | 一种4-嘧啶酮衍生物的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| US6310043B1 (en) | 1998-08-07 | 2001-10-30 | Governors Of The University Of Alberta | Treatment of bacterial infections |
| GB9821503D0 (en) | 1998-10-02 | 1998-11-25 | Novartis Ag | Organic compounds |
| FR2786770B1 (fr) * | 1998-12-04 | 2001-01-19 | Synthelabo | Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique |
| FR2804430B1 (fr) * | 2000-01-28 | 2002-03-22 | Sanofi Synthelabo | Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| US20020086871A1 (en) * | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
| US20050065178A1 (en) * | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| ES2365024T3 (es) * | 2004-05-07 | 2011-09-20 | Memory Pharmaceuticals Corporation | 1h-indazoles, benzotiazoles, 1,2-benzoisoxazoles, 1,2-benzoisotiazoles y cromonas, y preparación y usos de los mismos. |
| ATE493415T1 (de) * | 2004-10-20 | 2011-01-15 | Neurosearch As | Neue diazabizyklische arylderivate und medizinische verwendung dafür |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| TW201004963A (en) * | 2008-07-03 | 2010-02-01 | Targacept Inc | Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands |
| JP2013512922A (ja) * | 2009-12-07 | 2013-04-18 | ターガセプト，インコーポレイテッド | 神経型ニコチン性アセチルコリン受容体リガンドとしての３，６−ジアザビシクロ［３．１．１］ヘプタン |
-
2012
- 2012-08-10 TW TW101129077A patent/TW201311698A/zh unknown
- 2012-08-20 CN CN201280045308.7A patent/CN103797016A/zh active Pending
- 2012-08-20 US US14/239,817 patent/US20140249141A1/en not_active Abandoned
- 2012-08-20 MX MX2014002005A patent/MX2014002005A/es unknown
- 2012-08-20 PE PE2014000228A patent/PE20141247A1/es not_active Application Discontinuation
- 2012-08-20 WO PCT/US2012/051518 patent/WO2013028587A1/en active Application Filing
- 2012-08-20 AU AU2012299077A patent/AU2012299077A1/en not_active Abandoned
- 2012-08-20 JP JP2014527213A patent/JP2014524470A/ja active Pending
- 2012-08-20 KR KR1020147007275A patent/KR20140068079A/ko not_active Application Discontinuation
- 2012-08-20 EP EP12753884.1A patent/EP2748170A1/en not_active Withdrawn
- 2012-08-20 SG SG2014011126A patent/SG2014011126A/en unknown
- 2012-08-20 RU RU2014110971/04A patent/RU2014110971A/ru not_active Application Discontinuation
- 2012-08-20 BR BR112014004068A patent/BR112014004068A2/pt not_active IP Right Cessation
- 2012-08-20 CA CA2844764A patent/CA2844764A1/en not_active Abandoned
- 2012-08-21 AR ARP120103054A patent/AR087602A1/es not_active Application Discontinuation
- 2012-08-21 UY UY0001034281A patent/UY34281A/es not_active Application Discontinuation
-
2014
- 2014-02-09 IL IL230889A patent/IL230889A0/en unknown
- 2014-02-20 CL CL2014000417A patent/CL2014000417A1/es unknown
- 2014-03-20 CO CO14060707A patent/CO6920290A2/es unknown
- 2014-12-22 HK HK14112780.3A patent/HK1199251A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014004068A2 (pt) | 2017-03-14 |
| TW201311698A (zh) | 2013-03-16 |
| AU2012299077A1 (en) | 2014-03-13 |
| CO6920290A2 (es) | 2014-04-10 |
| WO2013028587A1 (en) | 2013-02-28 |
| CN103797016A (zh) | 2014-05-14 |
| KR20140068079A (ko) | 2014-06-05 |
| EP2748170A1 (en) | 2014-07-02 |
| MX2014002005A (es) | 2014-03-27 |
| PE20141247A1 (es) | 2014-10-12 |
| CL2014000417A1 (es) | 2014-09-26 |
| JP2014524470A (ja) | 2014-09-22 |
| US20140249141A1 (en) | 2014-09-04 |
| AR087602A1 (es) | 2014-04-03 |
| RU2014110971A (ru) | 2015-09-27 |
| CA2844764A1 (en) | 2013-02-28 |
| IL230889A0 (en) | 2014-03-31 |
| UY34281A (es) | 2014-02-28 |
| SG2014011126A (en) | 2014-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| IL227496B (en) | Pyrazolo[4,3–b]pyridines are converted as drugs | |
| IL229061B (en) | Antibody against 3h – 7b, polynucleotides encoding it, preparations containing it and its uses | |
| IL222977A0 (en) | Novel 3,5- disubstituted-3 h-imidazolo[5-b]pyridine and 3,5-disubstituted-3h-[1.2.3]triazolo[4,5]py | |
| EP2935214A4 (en) | 1,4-PYRIDONES COMPOUNDS | |
| ZA201307783B (en) | Tri-and tetracylic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent | |
| EP2687510A4 (en) | PROCESS FOR THE PREPARATION OF 2,3-DICHLORPYRIDINE | |
| PL2671884T3 (pl) | Nowe pochodne 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepin jako ligandy receptorów histaminowych typu H4 | |
| ZA201204143B (en) | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands | |
| HK1198586A1 (zh) | -二氟甲基- -二氫- 噁嗪- -胺衍生物 | |
| EP2692619B8 (en) | Saddle riding type vehicle | |
| IL232717B (en) | 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives | |
| IL230549A (en) | 3, 4-Dihydro-h1 - [8,1] Naphthyridinones are preserved in cyclopenta [c] pyrolytic with antibacterial activity | |
| EP2937326A4 (en) | PROCESS FOR THE PREPARATION OF 1, 3, 3, 3-TETRAFLUOROPROPENE | |
| IL221479A0 (en) | Triazolo [4,5-b] pyridin derivatives | |
| IL245849A0 (en) | A process for making a radioactive isotope of gallium | |
| ZA201503682B (en) | 3,3'-dinitro-5,5'-bistriazole-1,1'-diol | |
| EP2814797A4 (en) | PROCESS FOR 1,3,3,3-TETRAFLUORPROPES | |
| LU91997B1 (en) | Seat suspension mat, especially for vehicle seat | |
| PL2733262T3 (pl) | Zamiatarka do pojazdu dla dzieci, zwłaszcza pojazdu na padały | |
| EP2796439A4 (en) | PROCESS FOR PURIFYING (E) -1-CHLORO-3,3,3-TRIFLUOROPROPENE | |
| EP2756883A4 (en) | PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUORPROPES | |
| HK1199251A1 (en) | 1,4-diazabicyclo[3.2.2]nonanes as neuronal nicotinic acetylcholine receptor ligands 14-[322] | |
| EP2730584A4 (en) | PROTEIN-POLYPEPTIDE COMPLEX HAVING A SPECIFIC ACTION ON THE NERVOUS SYSTEM, PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| Tarigan | Tarigan |